Allograft-Reinforced Cyclodialysis Lowers Pressure After Trabecular Surgery Fails

Eyes with open-angle glaucoma that remain uncontrolled after a trabecular outflow procedure often enter a narrow therapeutic corridor. Medication burden is already high, further trabecular intervention may offer diminishing returns, and the next step has traditionally meant moving toward bleb-forming surgery with all of its downstream surveillance and complication concerns. This preprint tests a different sequence: restore access to the uveoscleral pathway with standalone allograft-reinforced cyclodialysis after prior trabecular outflow treatment has not achieved sufficient pressure control.

The biological logic is straightforward. Trabecular procedures attempt to improve conventional aqueous drainage through the trabecular meshwork and Schlemm’s canal, but glaucoma is not a single-pathway disease. The uveoscleral route bypasses that bottleneck, shunting aqueous across the ciliary muscle and suprachoroidal space in a more pressure-independent fashion. In an eye already exposed to a prior trabecular operation, this complementary mechanism may matter more than simply repeating the same outflow strategy.

Pressure Reduction Held Through 12 Months

The registry-based analysis drew from the multicentre CREST cohort and included 47 eyes that met eligibility criteria: at least one prior trabecular outflow procedure, no prior bleb-forming surgery, and at least 12 months of follow-up. Follow-up completion remained high, with 91.5% reaching the 12-month assessment. Baseline disease severity was not mild. Mean visual field deviation was −11.7 dB, a level consistent with moderate-to-advanced glaucoma, and nearly all eyes, 95.7%, were pseudophakic.

At entry, mean intraocular pressure was 22.5 mmHg with a 95% confidence interval of 20.1 to 24.9 while participants were already receiving a mean of 3.0 medications. In the per-protocol efficacy analysis, mean pressure fell by 6.1 mmHg, with a 95% confidence interval of 3.7 to 8.6, translating to a 25.0% reduction. The p value was below 0.001. Medication burden did not increase over that interval.

The pressure drop was not the sort of marginal change that often disappears in real-world follow-up. It crossed a clinically meaningful threshold for a cohort that had already exhausted a trabecular approach, and it did so without demanding additional drops or pills to preserve the effect.

A Conjunctiva-Sparing Pathway Matters When Surgical Options Narrow

Cyclodialysis creates a controlled communication between the anterior chamber and the supraciliary or suprachoroidal space. Reinforcement with an allograft is intended to stabilize that pathway and reduce the risk that the channel closes before durable benefit is established. In practical terms, the appeal lies in a conjunctiva-sparing approach that may preserve the tissue planes needed if later filtration surgery becomes unavoidable.

That sequence is especially relevant in patients who have already crossed the threshold for interventional glaucoma care. Once the trabecular system has been manipulated and pressure remains above target, the next choice is often not between treatment and no treatment, but between one surgical escalation and another. A device or technique that activates a different outflow route may therefore expand the options available before moving to bleb-dependent surgery.

Reoperation Remained Uncommon at 12 Months

Durability was captured with Kaplan–Meier analysis. Freedom from incisional reoperation at 12 months was estimated at 78.2%, with a 95% confidence interval of 61.8% to 88.2%. For a cohort selected because prior trabecular intervention had not been enough, that estimate suggests a reasonable short-term period of stability after the procedure.

Safety signals were similarly restrained in the reported follow-up. There were no vision-threatening, clinically significant adverse events associated with the procedure, including persistent hypotony, maculopathy, or other major complications. In glaucoma surgery, those complications are not abstract labels. Persistent overfiltration and hypotony-related maculopathy can erase the value of a successful pressure reduction by creating a new visual threat, so the absence of those events in this report carries real bedside weight.

A quieter safety profile also changes the interpretation of the efficacy signal. A pressure-lowering procedure can look attractive on paper, but if it trades elevated pressure for hypotony or other structural harm, the clinical equation collapses. Here, the reported balance leaned toward sustained pressure lowering without the trade-off of permanent vision loss in the observed period.

What the Cohort Can and Cannot Prove Yet

This is still a preprint, and that fact matters because the manuscript has not undergone peer review. The dataset is also modest in size, limited to 47 eligible eyes, and the report centers on a registry analysis rather than a randomized comparison. Those features do not negate the findings, but they do define the strength of inference: encouraging short-term evidence, not a final practice-changing verdict.

The study is most persuasive when read as a proof of concept for pathway sequencing in glaucoma. When trabecular surgery has not delivered enough IOP control, the uveoscleral route may provide a biologically distinct next step that does not require immediate commitment to bleb-forming surgery. The reported reduction in pressure, paired with unchanged medication burden and an absence of major safety concerns, makes that proposition plausible.

Still, the longer question remains whether the benefit persists beyond the first year, how it compares with established incisional alternatives in a controlled design, and which eyes are most likely to respond. Eyes with prior trabecular surgery are not all alike. Baseline anatomy, scarring tendency, disease stage, and prior medication exposure could all affect the durability of a cyclodialysis-based strategy.

The preprint’s central message is narrower than a broad claim of surgical superiority. In open-angle glaucoma that remains uncontrolled after a prior trabecular intervention, allograft-reinforced cyclodialysis produced meaningful 12-month pressure reduction without increased medication burden and without the major complications that often limit enthusiasm for more aggressive glaucoma surgery.

The next step is not philosophical. It is comparative data, longer follow-up, and a clearer sense of where this uveoscleral approach fits in the sequence of glaucoma care after trabecular failure.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA